Investigation of prostate resected weight on postoperative sexual dysfunction following transurethral resection of prostate surgery: a population-based study.
benign prostate hyperplasia
new-onset postoperative sexual dysfunction
population-based study
Journal
Therapeutics and clinical risk management
ISSN: 1176-6336
Titre abrégé: Ther Clin Risk Manag
Pays: New Zealand
ID NLM: 101253281
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
23
1
2019
pubmed:
23
1
2019
medline:
23
1
2019
Statut:
epublish
Résumé
Benign prostate hyperplasia, a common disease in elderly men, can be surgically treated with transurethral resection of the prostate (TURP). Postoperative sexual dysfunction is a major issue and is influenced by many factors. The present study aimed to assess whether the intraoperative resected prostate weight influences the probability of postoperative sexual dysfunction. This population-based study included 41,574 patients from the Nation Health Insurance Research Database who had undergone TURP once between 1997 and 2013. All patients were divided into three groups according to the resected prostate weight (low, medium, and high groups). Perioperative risk factors influencing sexual function were analyzed. The chi-squared test and Fisher's exact test were used to analyze differences in demographic data. The Cox proportional hazard regression analysis was used to analyze the HRs. All statistical analyses were two-sided, and a Of the 41,574 patients, 1,168 had postoperative sexual dysfunction after surgery. The incidence was not significantly different among the three resected prostate weight groups. Younger patients and patients with histories of chronic renal disease, ischemic heart disease, and obesity had higher prevalence of postoperative sexual dysfunction. Additionally, the onset time of sexual dysfunction was not significantly different among the three resected prostate weight groups. Among patients undergoing TURP in Taiwan, the resected prostate weight does not seem to be related to the presence or onset time of postoperative sexual dysfunction.
Sections du résumé
BACKGROUND
BACKGROUND
Benign prostate hyperplasia, a common disease in elderly men, can be surgically treated with transurethral resection of the prostate (TURP). Postoperative sexual dysfunction is a major issue and is influenced by many factors. The present study aimed to assess whether the intraoperative resected prostate weight influences the probability of postoperative sexual dysfunction.
METHODS
METHODS
This population-based study included 41,574 patients from the Nation Health Insurance Research Database who had undergone TURP once between 1997 and 2013. All patients were divided into three groups according to the resected prostate weight (low, medium, and high groups). Perioperative risk factors influencing sexual function were analyzed. The chi-squared test and Fisher's exact test were used to analyze differences in demographic data. The Cox proportional hazard regression analysis was used to analyze the HRs. All statistical analyses were two-sided, and a
RESULTS
RESULTS
Of the 41,574 patients, 1,168 had postoperative sexual dysfunction after surgery. The incidence was not significantly different among the three resected prostate weight groups. Younger patients and patients with histories of chronic renal disease, ischemic heart disease, and obesity had higher prevalence of postoperative sexual dysfunction. Additionally, the onset time of sexual dysfunction was not significantly different among the three resected prostate weight groups.
CONCLUSION
CONCLUSIONS
Among patients undergoing TURP in Taiwan, the resected prostate weight does not seem to be related to the presence or onset time of postoperative sexual dysfunction.
Identifiants
pubmed: 30666121
doi: 10.2147/TCRM.S186822
pii: tcrm-15-113
pmc: PMC6330969
doi:
Types de publication
Journal Article
Langues
eng
Pagination
113-118Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Eur Urol. 2003 Dec;44(6):637-49
pubmed: 14644114
Curr Urol Rep. 2004 Aug;5(4):251-7
pubmed: 15260924
Eur Urol. 2006 Jun;49(6):970-8; discussion 978
pubmed: 16481092
J Urol. 2006 May;175(5):1817-21
pubmed: 16600770
Int J Impot Res. 2010 Mar-Apr;22(2):146-51
pubmed: 19940854
Eur Urol. 2011 Oct;60(4):809-25
pubmed: 21726934
J Androl. 2012 May-Jun;33(3):427-34
pubmed: 21868751
Curr Urol Rep. 2012 Dec;13(6):433-40
pubmed: 23065462
BJU Int. 2013 Jul;112(1):109-20
pubmed: 23490008
Eur Urol. 2013 Jul;64(1):118-40
pubmed: 23541338
J Endocrinol Invest. 2013 Dec;36(11):1094-8
pubmed: 24445123
Arch Ital Urol Androl. 2015 Mar 31;87(1):8-13
pubmed: 25847889
Int J Urol. 2016 Jan;23(1):22-35
pubmed: 26177667
Medicine (Baltimore). 2016 Jun;95(24):e3862
pubmed: 27310968
Sex Med Rev. 2014 Jan;2(1):47-55
pubmed: 27784543
Transl Androl Urol. 2017 Apr;6(2):295-304
pubmed: 28540239
J Urol. 1995 May;153(5):1491-3
pubmed: 7536253
Br J Urol. 1998 Dec;82 Suppl 1:26-33
pubmed: 9883259